4/A//SEC Filing
Grooms Jamie Mark 4/A
Accession 0001179110-17-015343
CIK 0000805928other
Filed
Dec 12, 7:00 PM ET
Accepted
Dec 13, 7:44 PM ET
Size
9.9 KB
Accession
0001179110-17-015343
Insider Transaction Report
Form 4/AAmended
AxoGen, Inc.AXGN
Grooms Jamie Mark
Director
Transactions
- Sale
Common Stock
2017-12-06$26.22/sh−21,290$558,224→ 344,317 total - Sale
Common Stock
2017-12-07$26.47/sh−33,500$886,745→ 310,817 total - Sale
Common Stock
2017-12-08$26.37/sh−31,805$838,698→ 279,012 total
Footnotes (7)
- [F1]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $27.00. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]These shares of common stock include 132,883 shares held by the Jamie Grooms Trust, of which Mr. Grooms is the trustee.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.95. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.15 to $26.70. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]These shares of common stock include 108,883 shares held by the Jamie Grooms Trust, of which Mr. Grooms is the trustee.
- [F6]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017.
- [F7]Amended as a result of 2,300 shares sold on December 7, 2017 inadvertently not being disclosed. Such December 7, 2017 transaction has been revised resulting in a change in the aggregate number of shares sold and the weighted average sale price for such day, along with change in holdings after the December 7 and 8, 2017 transactions.
Documents
Issuer
AxoGen, Inc.
CIK 0000805928
Entity typeother
Related Parties
1- filerCIK 0001530935
Filing Metadata
- Form type
- 4/A
- Filed
- Dec 12, 7:00 PM ET
- Accepted
- Dec 13, 7:44 PM ET
- Size
- 9.9 KB